• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 6, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

McLean researchers awarded allowance for a method to treat PTSD with xenon gas

Bioengineer by Bioengineer
June 28, 2017
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Belmont, MA – Researchers from McLean Hospital have been issued a patent allowance for their invention involving the use of xenon gas to aid in the treatment of addiction and anxiety disorders such as post-traumatic stress disorder (PTSD). The allowance indicates that, pending administrative actions, a patent will be issued to Edward G. Meloni, PhD, an investigator in the Behavioral Genetics Laboratory at McLean Hospital and assistant professor of Psychiatry at Harvard Medical School and Marc J. Kaufman, PhD, director of the Translational Imaging Laboratory at McLean Hospital and associate professor of Psychiatry at Harvard Medical School.

The researchers found in an animal study that xenon gas works to block "reconsolidation," a memory process in which recalled memories are susceptible to modification. Blocking this process lessens the emotional impact of the memory of the traumatic event. According to Meloni, "the invention may supplement traditional cognitive therapy or 'talk therapy' with xenon gas administered to help PTSD patients cope better with their traumatic memories."

Meloni explained that the invention could be used during a psychotherapy session in a clinician's office. When talk therapy reactivates a traumatic memory, the patient would inhale the gas, which "will interfere with a neurobiological process that re-stores or 'reconsolidates' the memory back into the brain."

Meloni said the he believes the invention will mostly be used in clinical settings, "but we also envision having patients be able to self-administer the gas through a portable inhalation device when they experience flashbacks, cues that trigger the traumatic memory, or nightmares-all common symptoms of PTSD."

Nobilis Therapeutics, a biotechnology company that develops inhalation-based treatments using inert gases, has licensed the patent. Nobilis is developing a hand-held medical device for self-administration of xenon outside of the clinician's office, and is working to advance the use of the invention to treat patient populations with neurological and psychiatric disorders beyond PTSD.

###

McLean Hospital is the largest psychiatric affiliate of Harvard Medical School and a member of Partners HealthCare. For more information about McLean, visit mcleanhospital.org or follow the hospital on Facebook or Twitter.

Media Contact

Adriana Bobinchock
[email protected]
617-855-2110
@McLeanHospital

http://www.mcleanhospital.org

http://www.mcleanhospital.org/news/2017/06/27/mclean-researchers-awarded-allowance-method-treat-ptsd-and-other-disorders-xenon-gas

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Nurses’ Competence in Dementia Care: Current Insights

November 6, 2025

Ferroptosis in Diabetes: Insights from Research

November 6, 2025

Berberine boosts CYP3A4 expression through PXR activation

November 6, 2025

Novel Rhodanine–Sulfonate Compounds Inhibit Aldose Reductase

November 6, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1301 shares
    Share 520 Tweet 325
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    313 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    206 shares
    Share 82 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    138 shares
    Share 55 Tweet 35

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Nurses’ Competence in Dementia Care: Current Insights

Ferroptosis in Diabetes: Insights from Research

Berberine boosts CYP3A4 expression through PXR activation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.